Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which stimulates V1-receptors in the vascular bed and may change both central and brachial hemodynamics and plasma concentration of vasoactive hormones.

The purpose of the study is to measure the effects of tolvaptan on renal handling of water and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Regional Hospital Holstebro
• Collaborator: Aarhus University Hospital
• Treatments: Nitric Oxide; Tolvaptan

Criteria

Inclusion Criteria:

• Men and women, age 18-40 years

• Body Mass Index (BMI) 18,5-30 kg/m2

Exclusion Criteria:

• Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease

• Neoplastic disease

• Drug abuse

• Alcohol abuse

• Medical treatment except peroral anticontraceptive

• Pregnancy

• Smoking

• Abnormal blood and urine sample

• Abnormal ECG

• Blood donation within a month before examination

• Arterial hypertension (>140 mmHg systolic and/or 90 mmHg diastolic)